Vaxxas and CEPI Collaborate on Innovative mRNA Vaccine Platform
Vaxxas and CEPI Collaborate on Innovative mRNA Vaccine Platform
Vaxxas, a clinical-stage biotechnology company, is making strides in vaccine technology through its partnership with CEPI, the Coalition for Epidemic Preparedness Innovations. Together, they are working on a groundbreaking program involving a funding initiative of US$4.8 million (AU$7.2 million) aimed at developing needle-free, thermostable mRNA vaccines using the Vaxxas high-density microarray patch (HD-MAP) technology.
Significance of the Collaboration
This collaboration is vital in advancing the landscape of vaccine delivery, especially in the context of global accessibility and public health. Recent preclinical trials have shown promising results, notably in stability and immunogenicity. Vaxxas's technology allows for the efficient delivery of mRNA vaccines, which have demonstrated significant stability even under varying temperature conditions.
Key Achievements in Preclinical Trials
During the preclinical trials, Vaxxas successfully demonstrated the expression of a seasonal influenza antigen. This was achieved through the delivery of mRNA encapsulated in lipid nanoparticles (LNPs) via the HD-MAP platform. The findings indicated that when mRNA-LNPs are loaded onto the HD-MAP, they maintain stability at temperatures ranging from 2°C to 40°C for extended periods. Such performance can revolutionize the storage and distribution practices currently utilized in vaccine deployment.
Partnership with SK bioscience
To further bolster this initiative, Vaxxas is collaborating with SK bioscience, a leading global vaccine developer. This partnership focuses on advancing an mRNA vaccine targeting the Japanese Encephalitis Virus (JEV), which is moving towards a Phase I clinical study. By refining mRNA vaccine formulations, Vaxxas is setting the stage for a comprehensive evaluation through both in vitro and in vivo preclinical studies.
Addressing the Cold Chain Challenge
One of the pressing challenges with traditional mRNA vaccines is their stringent cold-chain storage requirements. The ability of Vaxxas’s HD-MAP technology to facilitate the distribution of heat-stable vaccines represents a significant improvement over conventional methods. This not only lowers costs but also eases the logistical constraints associated with vaccine delivery, particularly in remote or underserved regions.
Impact on Global Health
The implications of this program are profound as they may lead to broader access to life-saving mRNA vaccines. David L. Hoey, CEO of Vaxxas, emphasized the transformative potential of the HD-MAP technology in making vaccines more accessible to populations in need, thus enhancing global public health responses.
Future Prospects
Looking ahead, Vaxxas aims to push forward with its development efforts in 2025. If successful, the innovations brought forth could pave the way for self-administrable vaccine delivery methods, fundamentally changing the way vaccines are distributed and administered worldwide.
About Vaxxas
Vaxxas is dedicated to advancing the effectiveness of next-gen vaccines through its revolutionary HD-MAP technology. With successful trials involving over 500 participants and ongoing studies in infectious diseases, Vaxxas is positioned at the forefront of vaccine innovation.
About CEPI
Founded to accelerate vaccine development against epidemic threats, CEPI plays a crucial role in enhancing global health security. Its mission entails ensuring that vaccines are developed swiftly and efficiently, particularly for those in need during health emergencies.
Frequently Asked Questions
What is the purpose of the Vaxxas and CEPI collaboration?
The collaboration aims to develop needle-free, thermostable mRNA vaccines to improve global accessibility and response to health crises.
How does the HD-MAP technology work?
The HD-MAP technology delivers vaccines via tiny microprojections that penetrate the skin, efficiently targeting immune cells without the use of traditional needles.
What challenges do mRNA vaccines face?
Current mRNA vaccines require strict cold-chain storage and distribution, posing logistical challenges, especially in low-resource settings.
What type of vaccine is Vaxxas developing with SK bioscience?
Vaxxas is developing an mRNA vaccine targeting the Japanese Encephalitis Virus (JEV) in partnership with SK bioscience, moving towards clinical trials.
When is Vaxxas planning to progress with the next stage of development?
Vaxxas plans to move forward with its development work in 2025 to continue progressing its innovative vaccine platform.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
